As Hurricane Michael — the strongest hurricane in history to hit the Florida Panhandle — continues to surge through the Southeast with damaging winds and flood-causing rains, MedImpact is committed to providing natural disaster support to our clients and members.
The U.S. Food and Drug Administration (FDA) recently approved Takhzyro (lanadelumab-flyo) as the first preventive monoclonal antibody to treat hereditary angioedema (HAE) to help prevent attacks in patients 12 years and older. HAE is a rare and potentially life-threatening genetic disease that can cause unpredictable, debilitating episodes of painful swelling in the limbs, abdomen and airway.